Specifically, the median overall survival was 10 months for patients treated with chemotherapy alone versus 13 months for patients treated with chemotherapy plus ICI in patients whose tumor transformed after developing resistance to EGFR-TKI therapy (Hazard ratio 0.75, 0.36−1.56) (10). Here, EGFR is linked to neoplasm.